Shingles Pain That Won’t Stop? Understanding Postherpetic Neuralgia

Shingles pain that outlasts the rash is postherpetic neuralgia (PHN). The chickenpox virus wakes up and injures the nerve. The nerve then keeps misfiring as burning, stabbing or electric pain where the rash was. The 8% capsaicin patch, lidocaine patches and oral nerve-pain drugs treat it.

For most people, shingles is a miserable few weeks, and then it’s over. But for a sizable minority, the rash heals and the pain doesn’t. It settles into lasting, often severe nerve pain that can go on for months or years. This is postherpetic neuralgia (PHN), one of the most common and most distressing kinds of nerve pain. This article explains how a childhood chickenpox virus can come back decades later to injure nerves. It covers what makes the pain last, how it is treated, and how it can be prevented.

Why does the chickenpox virus come back as shingles?

Shingles is caused by the varicella-zoster virus (VZV), the same virus that causes chickenpox. After a childhood bout of chickenpox, the virus does not leave the body. It hides in the dorsal root ganglia. These are clusters of sensory nerve cell bodies that sit next to the spinal cord. The virus lies dormant there, sometimes for decades. The immune system holds it in check.

When immunity fades, the virus can wake up again. That can happen with age, illness, stress, or conditions and treatments that weaken the immune system. The virus travels back down the sensory nerve to the skin. There it causes the painful, blistering rash of shingles in a band along that nerve’s path. But the damage isn’t only skin-deep. As the virus wakes, it inflames and injures the nerve and its ganglion along the way.

Why does shingles pain last after the rash heals?

In postherpetic neuralgia, the nerve injury from shingles leaves the sensory pathway damaged and out of balance. The injured nerves become overexcitable and misfire. The pain-processing system itself can also become sensitized. Then even light touch on the healed skin triggers severe pain. This is called allodynia. The result is lasting burning, stabbing, or electric pain where the rash was. It often comes with extreme tenderness.

Several factors raise the risk of PHN. The biggest is older age, and the risk climbs a lot with each decade. A more severe first bout of shingles also raises it. This is why prevention and early treatment matter so much.

How is postherpetic neuralgia treated?

PHN is hard to treat, but there are real tools. They work best when combined and fitted to the person.

Early antiviral treatment of the shingles bout can help. It should start promptly, within the first days of the rash. It can cut how bad the outbreak gets and how long it lasts. It may also lower the risk of lasting pain. That is one reason to get care quickly when shingles appears.

For established PHN, there are topical therapies you put on the skin. One is the high-concentration 8% capsaicin patch. It is FDA-approved for postherpetic neuralgia. It works by quieting the overactive pain fibers in the affected skin, as the capsaicin article explains in detail. Lidocaine patches are another. There are also oral neuropathic-pain medications, such as gabapentinoids and certain antidepressants. PHN often stays in one area. So skin treatments, which do not act on the whole body, are especially useful. They help you avoid whole-body side effects.

Beyond symptom control, a repair-and-support approach addresses the injured nerve terrain itself. The video notes measures aimed at supporting recovery. These include cannabinoid-based therapies and glutathione. To be accurate, here is where they stand. Cannabinoids have a growing but still-evolving evidence base for nerve pain. Glutathione support for nerve recovery makes biological sense, but it is not a proven cure. Both are add-ons (adjuncts) used within a personal plan guided by a physician. They are not established standalone treatments.

Can postherpetic neuralgia be prevented?

The single most effective way to deal with postherpetic neuralgia is to prevent the shingles bout that causes it. The recombinant shingles vaccine (Shingrix) is highly effective at preventing shingles, and so at preventing PHN. It is recommended for older adults and certain people with weak immune systems (immunocompromised). Are you in an at-risk group and not yet vaccinated? Then this is a talk worth having with a physician. Preventing the outbreak is far easier than treating the pain it can leave behind.

Where this fits

Postherpetic neuralgia is one of the infection-related drivers of nerve pain. The neuropathies of metabolic disease are spread out and start at the longest nerves first. PHN is different. It usually stays in the nerve area the shingles outbreak hit. That distinct pattern helps identify it. It also shapes the local, terrain-supportive approach to treatment.

Frequently asked questions

Key takeaways

• Shingles comes from varicella-zoster virus waking up in the dorsal root ganglia and injuring the nerve.
• Postherpetic neuralgia is the lasting nerve pain that can follow, driven by nerve damage and sensitization.
• Risk rises sharply with age and with a severe initial outbreak.
• Treatment combines skin treatments (including the FDA-approved 8% capsaicin patch), oral drugs, and terrain support. Cannabinoids and glutathione are adjuncts, not proven cures.
• The shingles vaccine is the most effective way to prevent PHN.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. Take the free Nerve Damage Score or call (314) 886-5739 or text (314) 886-5902.

References

1. Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. 2014;371:1526–1533.
2. Gershon AA, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015.
3. Backonja M, et al. NGX-4010 (capsaicin 8% patch) for postherpetic neuralgia: randomized studies. Lancet Neurol. 2008.
4. Dooling KL, et al. Recommendations of the ACIP for use of recombinant zoster vaccine (Shingrix). MMWR. 2018.